Compugen’s COM701 shows durable anti-tumor activity in ovarian cancer

Compugen announced publication of ePosters by ESMO Immuno-Oncology Congress 2022 showing that Compugen’s COM701 in dual and triple combination with nivolumab +/- BMS-986207 demonstrated preliminary durable anti-tumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile. Oladapo Yeku, Director of Translational Research, Massachusetts General Hospital, said, "It is encouraging to see anti-tumor activity in these heavily pretreated heterogeneous platinum resistant ovarian cancer patients, with a disease control rate of 45% following both dual and triple combination treatment. The combination of drugs was well tolerated with a favorable safety profile consistent with what has previously been reported for COM701 with nivolumab +/- BMS-986207. Because of the anti-tumor activity and tolerability of the combination, our patients on the study reported an improvement in quality of life. I look forward to seeing the further development of COM701 combinations in patients with platinum resistant ovarian cancer." Based on the data reported in the different studies, Compugen is planning to pursue two studies, with the purpose to strengthen the data it has already published and to build a path to future registration studies: the first, in up to 20 patients with metastatic MSS-CRC, immune checkpoint inhibitor naive patients with less than or equal to 2L of prior therapy, treated with a triple combination of Compugen’s anti-PVRIG, COM701, and its own anti-TIGIT, COM902, and pembrolizumab. Enrolment is expected to be completed in 2023. The second is a follow up study currently under design in platinum resistant ovarian cancer immune checkpoint inhibitor naive patients. Compugen expects to share initial findings by the end of 2023.